GYRE Therapeutics, Inc. (GYRE)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $6.47
- As of
Kresmion compiles this page from GYRE's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
GYRE THERAPEUTICS, INC. (GYRE): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-01.
See the full GYRE dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for GYRE on one page. Preview it with sample data, then open it live with a free account.
Preview the GYRE dossierActive signals for GYRE
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 30.7%, EPS $-0.12 vs $-0.0918 estimate
- lowEARNINGS_MISS
Q2-2025: EPS $0.02 vs $0.0306 estimate, -0.01 on a near-zero consensus
- lowEARNINGS_BEAT
Q3-2025: EPS $0.08 vs $0.0272 estimate, +0.05 on a near-zero consensus
- mediumEARNINGS_MISS
Q4-2025: Missed consensus by 13.5% - EPS $0.05 vs $0.0578 estimate
- mediumEARNINGS_BEAT
Q1-2026: Beat consensus by 39.8% - EPS $-0.045 vs $-0.0748 estimate
FREE, NO ACCOUNT
Every signal on GYRE, as it fires
New filings, 13F moves and cross asset signals on GYRE land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in GYRE (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 403783103 · 2026Q2 | $122K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, GYRE
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
GYRE against its peers
GYRE's operating margin of 9.9% ranks in the 77th percentile of 10 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | GYRE | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 117M USD | 42.7M USD | 79 | 11 |
| Operating margin | 9.9% | -142.7% | 77 | 10 |
| Net margin | 8.5% | -132.8% | 68 | 10 |
| Return on equity | 9.3% | -39.4% | 83 | 19 |
| P / E | 323.5x | n/a | n/a | 2 |
| 1 year | -19.2% | -3.2% | 36 | 17 |
Peers (20): ACHV, SLDB, FDMT, CADL, XOMA, MDXG, VSTM, IMMX, PHAR, GERN, DSGN, ZVRA, ANNX, AVTX, PRME, LXRX, OLMA, WVE, AVBP, SGP. Left out: IVA (period gap), HELP (period gap), APMD (no annual filing), OBX (no annual filing), ATTO (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (GYRE: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow GYRE on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to GYRE for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.